Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Company Deals

Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million

Fineline Cube Jul 8, 2026
Company Deals

MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001

Fineline Cube Jul 8, 2026
Company Deals

Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China

Fineline Cube Jul 8, 2026
Policy / Regulatory

China Adds Methoxyethyl Etomidate, Loretomidate and Solriamfetol to Controlled Psychotropic Substances List

Fineline Cube Jul 8, 2026
Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline

Fineline Cube Jul 8, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors

Fineline Cube Jul 8, 2026
Company Drug

Innovent Biologics’ Ipilimumab NDA Accepted by CDE with Priority Review for Colon Cancer

Fineline Cube Feb 24, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced that the Center for Drug Evaluation (CDE), National...

Policy / Regulatory

AI in Healthcare: The Impact of DeepSeek Technology and Industry Developments

Fineline Cube Feb 23, 2025

The integration of advanced AI technologies into healthcare is revolutionizing the industry, and the recent...

Policy / Regulatory

In-Depth Analysis of the National Healthcare Security Policy: A Guide to Key Reforms and Implications

Fineline Cube Feb 22, 2025

The National Healthcare Security Administration (NHSA) has unveiled its 2025 priority action list, focusing on...

Policy / Regulatory

State Council’s Draft Plan Boosts Innovative Drug Development via Medical Insurance Reforms

Fineline Cube Feb 22, 2025

The State Council has released a second draft proposal outlining measures to support the high-quality...

Company Medical Device

Roche Unveils Sequencing by Expansion (SBX) Technology for Next-Generation Sequencing

Fineline Cube Feb 22, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced the presentation of its proprietary sequencing...

Policy / Regulatory

Shanghai Issues Legal Guidebook for Innovative Drug Marketing

Fineline Cube Feb 22, 2025

The Shanghai Municipal Market Supervision Administration Bureau has delivered a legal guidebook tailored for innovative...

Policy / Regulatory

China Outlines Drug Pricing Reforms, Encourages Insurance Funds for Innovation

Fineline Cube Feb 22, 2025

The Chinese government has released a set of opinions detailing the establishment of a new...

Company Drug

Roche’s Tecentriq Wins Japan Approval for Alveolar Soft Part Sarcoma

Fineline Cube Feb 21, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) and its Japanese partner Chugai Pharmaceutical Co.,...

Company Drug

GSK’s Nucala Receives NMPA Review for COPD Treatment

Fineline Cube Feb 21, 2025

GSK plc (LON: GSK, NYSE: GSK) announced that the National Medical Products Administration (NMPA) has...

Company Drug

Nuwacell Biotech’s NCR101 Approved for ILD Clinical Study by China’s CDE

Fineline Cube Feb 21, 2025

According to the Center for Drug Evaluation (CDE) website, China-based Nuwacell Biotechnology Co., Ltd. has...

Company

Baxter International Reports Q4 2024 Revenues of USD 2.75B, Up 2% YOY

Fineline Cube Feb 21, 2025

Baxter International (NYSE: BAX) announced its fourth-quarter 2024 financial results, reporting revenues of USD 2.75...

Company Deals Medical Device

Horimed Raises USD 13.8M to Advance Optical and Ultrasonic Imaging Tech

Fineline Cube Feb 21, 2025

Horimed, a Tianjin-based medical device firm specializing in optical and ultrasonic medical imaging technology and...

Company Deals

Gene Cradle and Byongen Therapeutics Partner on Next-Generation DMD Gene Therapies

Fineline Cube Feb 21, 2025

Gene Cradle and Byongen Therapeutics, both Beijing-based gene therapy specialists, have formed a strategic alliance...

Company Drug

Bristol-Myers Squibb’s Opdivo Shows Survival Benefit in CheckMate-816 Study

Fineline Cube Feb 21, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) announced the final analysis of overall survival (OS) data from...

Company Drug

Corxel Pharmaceuticals to Test JX10 in Acute Ischemic Stroke Patients with NMPA Approval

Fineline Cube Feb 21, 2025

China-based Corxel Pharmaceuticals (CORXEL) has received approval from the National Medical Products Administration (NMPA) to...

Company Deals

Harbour BioMed and Insilico Medicine Partner on AI-Powered Antibody Development

Fineline Cube Feb 21, 2025

China-based Harbour BioMed (HKG: 2142) announced a strategic partnership with Insilico Medicine, a generative artificial...

Company Drug

Gilead’s Livdelzi Receives Conditional EC Approval for Primary Biliary Cholangitis

Fineline Cube Feb 21, 2025

US-based Gilead Sciences Inc. (NASDAQ: GILD) announced that it has received conditional approval from the...

Company Deals

FibroGen to Sell China Subsidiary to AstraZeneca for ~$160M, Roxadustat Rights Included

Fineline Cube Feb 21, 2025

US-based biopharma FibroGen Inc. (NASDAQ: FGEN) has entered into an agreement to sell its China...

Company Deals

Waterdrop Integrates DeepSeek AI to Boost Insurance Ecosystem

Fineline Cube Feb 21, 2025

China-based Waterdrop Inc. (NYSE: WDH), a crowdfunding-based health insurance platform, announced a strategic integration with...

Company Drug

Boehringer Ingelheim Launches LENTICLAIR Study for CF Gene Therapy BI 3720931

Fineline Cube Feb 21, 2025

German pharmaceutical company Boehringer Ingelheim announced the initiation of the Phase I/II LENTICLAIR study for...

Posts pagination

1 … 235 236 237 … 692

Recent updates

  • Jenscare’s LuX-Valve Plus Secures CE Mark as World’s Second Transcatheter Tricuspid Valve Replacement
  • Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3/4 Inhibitor TQC3721
  • Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline
  • Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors
  • AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Jenscare’s LuX-Valve Plus Secures CE Mark as World’s Second Transcatheter Tricuspid Valve Replacement

Others

Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3/4 Inhibitor TQC3721

Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.